GSK presents case to expand use of its lupus drug in patients with kidney disease, but the field is evolving. How long will the monopoly last?
In 2011, GlaxoSmithKline’s Benlysta became the first biologic to win approval for lupus patients. Nine years on, the British drugmaker has unveiled detailed positive results …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
